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ABSTRACT
Kelch-like ECH-associated protein 1 (Keap1) plays an important regulatory role in the
Nrf2-dependent oxidative stress response pathway. It functions as a repressor of Nuclear
factor erythroid 2-related factor 2 (Nrf2), a key transcription factor that initiates the
expression of cytoprotective enzymes during oxidative stress to protect cells from
damage caused by reactive oxygen species. Recent studies show that mutations of Keap1
can lead to aberrant activation of the antioxidant pathway, which is associated with
different types of cancers. To gain a mechanistic understanding of the links between
Keap1 mutations and cancer pathogenesis, we have investigated the molecular effects of
a series of mutations (G333C, G350S, G364C, G379D, R413L, R415G, A427V, G430C,
and G476R) on the structural and target recognition properties of Keap1 by using nuclear
magnetic resonance spectroscopy, circular dichroism, and isothermal titration
calorimetry. Depending on their locations in the protein, these mutations are found to
exert differential effects on the protein stability and target binding. Together with the
proposed Hinge-and-Latch mechanism of Nrf2/Keap1 binding in literature, our results
provide important insight into the molecular impact of different somatic mutations on
Keap1’s function as a Nrf2 repressor.
SUMMARY STATEMENT (40 words)
We have elucidated the molecular effects of nine cancer-associated somatic mutations of
Keap1, an important regulator of the Nrf2-mediated oxidative stress response, on the
structural integrity and target recognition properties of the protein by using multiple
biophysical techniques.
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INTRODUCTION
The Nrf2/Keap1 antioxidant pathway plays critical roles both in chemoprevention
and cancer pathogenesis [1-4]. The transcription factor Nuclear factor erythroid 2-related
factor-2 (Nrf2) induces the cellular defenses against reactive oxygen species and toxic
substances by initiating the transcription of an array of cytoprotective genes, which are
essential for the elimination of electrophilic and oxidative stresses before damage is
caused to the cellular macromolecules [5, 6]. Under normal conditions, its activity is
suppressed by Keap1 (Kelch-like ECH-associated protein 1) in conjunction with the
Cullin 3 (Cul3) E3 ubiquitin ligase complex via ubiquitin-mediated proteasomal
degradation [5, 7-9]. In the presence of oxidative stress, however, specific cysteine
residues in Keap1 are subjected to modifications by the oxidants [10]. The modified
Keap1 is incapable of targeting Nrf2 for ubiquitination, allowing Nrf2 to translocate into
the nucleus to initiate gene transcription [6].
Accumulation of Nrf2 in the nucleus however, can lead to aberrant cytoprotective
gene expression if not regulated [11-13]. Keap1 is a cytosolic protein that lacks a nuclear
localization signal and cannot enter the nucleus on its own to regulate Nrf2 levels [14].
Recent studies have revealed that the Keap1 protein can be shuttled to the nucleus in
complex with Prothymosin α (ProTα), an intrinsically disordered protein that contains a
nuclear localization signal [14]. Once in the nucleus, Keap1 mediates ubiquitination and
proteasomal degradation of Nrf2, causing Nrf2 to return to its basal level. This
regulatory mechanism is essential as the continuous expression of cytoprotective proteins
can promote cell proliferation leading to tumorigenesis [1, 15, 16].
The Keap1 is comprised of five domains (Figure 1A), the N-terminal domain, the
Broad complex, Tramtrack and Bric-a-Brac (BTB) domain, the intervening region (IVR),
the Kelch domain, and the C-terminal region, and all these domains contribute to Nrf2
repression. The N-terminal, BTB, IVR and the C-terminal regions contain critical
cysteine residues that are important for Keap1 activity [17-20]. The BTB domain is also
responsible for Keap1 dimerization. This domain, together with the IVR domain,
mediates the Keap1 interaction with the Cul3-E3 ligase complex required for the
ubiquitination of Nrf2 [7, 8, 21]. The Kelch domain is responsible for target recognition.
Besides Nrf2 and ProTα, the domain has also been shown to interact with WTX [22], p62
[23], PGAM5 [24], PALB2 [25], FAC1 [26], and IKKβ [27] to name a few [28]. In the
case of Nrf2, the N-terminal Neh2 domain of the protein harbors two Kelch-binding
motifs, the ETGE and DLG motifs, that interact with Keap1 through a “Hinge and Latch”
mechanism: one Kelch domain of the Keap1 dimer recruits the Nrf2 by first forming a
complex with the high binding affinity ETGE motif and then the second Kelch domain of
the dimer captures the weaker DLG motif of the same Nrf2 protein [29, 30]. This
binding mechanism allows the lysine residues located in between these two motifs in the
Neh2 domain to be properly positioned for ubiquitination [9, 29, 30]. On the other hand,
other targets of Keap1 like ProTα form a complex with the Kelch domain in a one to one
stoichiometry [31].
Over 200 somatic mutations within Keap1 have been reported in various types of
cancer tissues and cancer-derived cell lines [12, 15, 16, 32-34]. Several of them have
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been shown to be defective in inhibiting Nrf2 activity [15, 16, 35], resulting in
constitutive expression of cytoprotective enzymes in cancer cells thus promoting cell
survival [11]. It has been speculated that these mutations compromise Keap1’s structural
integrity, rendering it incapable of promoting the ubiquitination of Nrf2 [11, 36].
However, only a few studies of the structural and target-binding properties of these
mutants have been carried out to date [32, 36]. Therefore, the molecular links between
these mutations and the diseases remain poorly understood.
To address this problem, we set out to elucidate the effects of disease-associating
missense mutations on the structural integrity and target recognition of Keap1 by using
nuclear magnetic resonance (NMR) spectroscopy, circular dichroism (CD)
spectropolarimetry and isothermal titration calorimetry (ITC). We have chosen to focus
on the Kelch domain (residue 321-609) of Keap1 in this study. Importantly, close to 50%
of the missense somatic mutations identified in Keap1 so far are found to reside in this
domain (based on the data in the database of the Catalogue of Somatic Mutations in
Cancer-COSMIC [37]). Crystallographic studies show that the Kelch domain adopts a
six-bladed β-propeller conformation (Figure 1B) with several conserved amino acids that
are important for maintaining the hydrogen bond network, linking the propeller blades
and forming the hydrophobic core of the protein [36, 38, 39]. In particular, there is a
conserved glycine doublet found in each blade of the Kelch domain. These two glycine
residues are involved in an intrablade hydrogen bond network that may be instrumental in
the folding of individual blade structures. Both the ETGE and DLG motifs of Nrf2, as
well as ProTα are found to bind to the same positively charged pocket located at the
mouth of the central tunnel of the Kelch β-propeller [36, 40, 41]. The binding interface
of Kelch with targets is demonstrated in the crystal structure of Neh2-ETGE peptide
bound to the Kelch domain shown in Figure 1B [36].
We have investigated the effects of nine cancer-associated somatic mutations
[11], G333C, G350S, G364C, G379D, R413L, R415G, A427V, G430C, G476R, on the
target recognition and structural integrity of the Kelch domain of Keap1 (Table S1) [11,
12, 15, 16, 33, 35, 38]. These mutants can be divided into three categories based on their
location in the Kelch domain. The R415 residue is one of the conserved Arg residues
located in the positively charged vicinity in the bottom face of the propeller (Figure 1C)
and it is directly involved in the interface formation with ProTα and Nrf2 [36, 38, 40].
The G364C and R413L mutants are also included in the same category as the R415G.
Even though these two residues do not directly participate in target binding, they are both
next to residues that are involved in the ProTα and Nrf2 interactions (Figure 1C) [36, 38,
40]. Conversely, the second set of mutations, G350S and A427V, are distant from the
binding interface. The G350S as shown in Figure 1D is at the opposite side of the basic
pocket, and the A427V is found within a β-strand of blade III of the propeller. The last
group, containing G333C, G379D, G430C, and G476R, are mutations that occur in the
conserved double glycine repeats located in different blades (Figure 1E) [39]. Three of
these four mutations, G333C, G379D and G430C, occur in the second position of the GG
repeat while the G476R occurs in the first position of the doublet. Since these glycine
residues are expected to play an important structural role in the Kelch domain, it is
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important to assess the impacts of these mutations on the domain’s structural integrity
and function.
NMR and ITC were used to examine the interactions between Nrf2/ProTα and the
Kelch mutants. Nrf2 and ProTα have been shown to have the strongest and the weakest
binding affinity, respectively, to the wild-type Kelch domain among many of the known
partners studied [42]. Additionally, we have completed the backbone NMR chemical
shift assignment of the 34 kDa Kelch domain of human Keap1 [43]. This affords an
effective way to probe the conformational changes induced upon mutating specific
residues in the Kelch domain and provides a manner to observe regions important for
target binding. Our results show that these somatic mutations exert differential effects on
the structural integrity and target recognition properties of Keap1, implying that their
molecular links to the cancer pathogenesis can be very distinct.
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MATERIALS AND METHODS
Cloning, expression and purification of Keap1-Kelch variants
Mutant constructs of the Kelch domain were generated using the QuikChange II
site-directed mutagenesis kit (Stratagene) with the wild-type human Kelch domain
(residues 321-609 of Keap1) in the prokaryote expression vector pDEST17 (Life
Technologies) [39]. Following are the primers used for the mutations: G333C-5'ctacaccgcgggctgctacttccgaca-3'; G350S-5'-caaccccagtgacagcacctggctccg-3'; G364C-5'aggtgccgcggagctgcctggccggctgcg-3'; G379D-5'-gtacgccgtgggcgacaggaacaactcgcc-3';
R413L-5'-atgagcgtgccccttaaccgcatcggg-3'; R415G-5'-agcgtgccccgtaacggcatcggggtgg-3';
A427V-5'-gatggccacatctatgtcgtcggcggct-3'; G430C-5'-atatgccgtcggctgctcccacggctg-3';
G476R-5'-tgctttatgccgtgaggggctttgacggg-3'. Wild-type and mutational variants (G333C,
G350S, G364C, G379D, R413L, R415G, A427V, G430C, G476R) were expressed and
purified following the protocols described in [31].
Neh2 constructs, expression and purification
The gene fragment of human Neh2 domain of Nrf2 (amino acid residues M1G98) was cloned out from the full length Nrf2 (purchased from Invitrogen; NM_006164)
and then inserted into the Gateway pDEST17 vector. The Neh2ΔETGE mutant (deletion
of 79ETGE82 from Neh2) was constructed from the full-length Neh2 fragment using the
QuikChange II site-directed mutagenesis kit (Stratagene). For each construct, a Tobacco
Etch virus (TEV) cleavage recognition site, ENLYFQG, was inserted between the
histidine tag and the Neh2 fragment. Three constructs were transformed into the Rosetta
2 (DE3)pLysS (Novagen) strain of Escherichia coli (E. coli) for protein expression in M9
media. Cells were grown at 37°C and protein over-expression was induced at an OD600
of 0.6 with 0.5 mM of isopropyl β-D-thiogalactopyranoside (IPTG, BioShop). The cells
were allowed to grow overnight at 25°C before harvesting. The Neh2 protein and its
variants were purified batch wise by Nickel-Sepharose (GE Healthcare) affinity
chromatography, followed by his-tag removal using TEV protease at 25°C for 21 hours.
Uncleaved Neh2 and the his-tagged TEV protease were then removed by NickelSepharose affinity chromatography. The final protein sample was analyzed on SDSPAGE for purity and dialyzed into 50 mM sodium phosphate buffer, 100 mM NaCl, 1
mM DTT, pH 7.0 for NMR and ITC experiments.
Peptides
The ProTα-ENGE peptide (> 98% purity), 33APANGNANEENGEQEADNEV52,
and the Neh2-ETGE peptide (> 98% purity), 69AFFAQLQLDEETGEFL84, were ordered
from GenScript USA Inc. The Neh2-DLG peptide, 20IDILWRQDIDLGVSREVFDF39,
was ordered from the Tufts University Core Facility with a purity level above 95%. The
lyophilized peptides were dissolved and dialyzed into 50 mM sodium phosphate buffer,
100 mM NaCl, and 1 mM DTT for ITC and NMR experiments.
Nuclear magnetic resonance (NMR) experiments
For the backbone resonance assignment of the Kelch domain of human Keap1,
NMR experiments were performed at 25 °C on a Bruker Avance 800 MHz (National
University of Singapore) spectrometer equipped with a cryogenic probe. A 600 µM 2H15
N-13C labeled sample of the Kelch domain was used to acquire 1H-15N-HSQC,
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HN(CO)CACB, HNCACB, and 15N-NOESY-HSQC spectra for sequential assignment of
the protein. The data was processed with NMRPipe [44] and analyzed using CARA
(http://cara.nmr.ch). The chemical shifts were deposited in the Biological Magnetic
Resonance Bank (accession number 19992).
15

N-labeled samples of the Kelch domain were prepared at a 200 µM
concentration for the ligand-binding NMR experiments. 1H-15N HSQC experiments were
performed on a Varian INOVA 600 MHz spectrometer with a cryogenic probe (UWO
Biomolecular NMR facility) at 25 °C. Data was analyzed using NMRPipe [44] and
NMRView [45].
Circular Dichroism (CD) Spectropolarimetry
Wild-type and Kelch mutant protein solutions (~2.2 mg/mL) were each prepared
in 50 mM sodium phosphate buffer, 100 mM NaCl, 1 mM DTT, pH 7.0. Far-UV CD
spectra were obtained in a 0.1 mm cuvette using a Jasco J-810 spectropolarimeter
(Easton, MD), at 25 °C for wavelengths ranging from 190-260 nm. The final curves for
each sample represent the mean of twenty separate scans. The CD data (θ, in
millidegrees) were converted to mean residue ellipticity ([θ]) using standard formula and
the software supplied by the manufacturer. The programs SELCON3, CDSSTR, and
CONTIN provided by the DichroWeb were used to deconvolute the CD spectra [46].
Isothermal Titration Calorimetry
ITC experiments were carried out on a MicroCal™ VP-ITC instrument. All
purified protein samples were dialyzed into 50 mM phosphate buffer with 100 mM NaCl
and 1 mM DTT at pH 7.0. In typical experiments, wild-type Kelch and mutational
variants were prepared to a concentration of ~15 µM for the Neh2-ETGE peptide (~150
µM) titrations and ~60 µM for the ProTα peptide (~800 µM) and Neh2-DLG peptide (~11.5 mM) titrations. Kelch or its mutational variants were loaded into the 1.42-mL cell,
and ligands were loaded into the syringe (300 µL). For the full-length Neh2 and
Neh2ΔETGE experiments with the wild-type and mutants of Kelch, the Kelch was loaded
into the syringe and the Neh2 proteins were loaded into the cell. Titrations were
performed at 25 °C (unless specified otherwise) starting with initial injection of 3 µL,
followed by 59 injections of 5 µL, with spacing of 240 seconds to 300 seconds. For the
Neh2ΔETGE construct, titrations were performed at 25 °C, 20 °C, 15 °C, 10 °C and 5 °C.
The buffer blank was performed under the same conditions and showed negligible heats
of binding. The dissociation constant (Kd), stoichiometry of binding (n), binding
enthalpy (ΔH), and entropy (ΔS) were obtained by fitting the data to a single-site binding
model with the data analysis software (Origin 7) provided by the manufacturer.
Baselines were subtracted from final data using the Origin software. For the full-length
Neh2 experiments, the data were fitted either to a two-site binding model (wild-type
Kelch, G350S, and A427V) or a one-site-binding model (G364C and R415G). Protein
concentrations were confirmed by amino acid analysis (Advanced Protein Technology
Centre, The Hospital for Sick Children, Toronto, ON).
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RESULTS
Mutations exert differential effects on the solubility of the Kelch domain of Keap1
The wild-type Kelch domain of human Keap1 was over-expressed in E. coli and
purified by the procedure described previously [31]. Four of the Kelch mutants, G350S,
G364C, R415G and A427V, were found to have similar solubility as the wild-type and
were purified with comparable yields. The R413L, G333C, G379D, G430C and G476R
mutants, on the other hand, were found almost exclusively in the insoluble fractions
under various over-expression conditions tested. We selected to purify the G333C,
G379D, and the R413L proteins from inclusion bodies using 8 M Urea and subjected to
refolding. Severe protein aggregation occurred upon refolding and only a small amount
of soluble protein was obtained for the three mutants. The signals observed in the 1H-15N
HSQC spectra (Figures S1A & B) of G333C and G379D proteins were broad and poorly
dispersed in the proton dimension, suggesting that both mutants were aggregated. While
the 1H-15N HSQC spectrum of R413L (Figure S1C) resembles that of a folded protein;
however, we were unable to obtain a stable (even at 4 °C) high purity protein sample.
Probing structural changes of the Kelch domain upon mutations by CD and NMR
CD and NMR were used to identify the effects of missense mutations on the
overall folding and local conformation of the Kelch domain. The CD results revealed
that the β-sheet secondary structure content, observed in the wild-type Kelch domain, is
preserved in G364C, G350S, R415G and A427V (Figure S2). The percentages of β-sheet
and disordered regions estimated from the deconvolution of CD spectra are almost
identical to the wild-type protein (Table S2), strongly suggesting that these four
mutations do not have a significant effect on the overall fold of the Kelch domain.
We then used NMR spectroscopy to investigate the effects of somatic mutations
on the local structural changes and ligand-binding of the Kelch domain. To be able to
monitor the site-specific conformational changes upon mutation and target binding,
backbone chemical shift assignment of the 34-kDa human Kelch domain was performed.
1
HN, 15N, 13Cα, 13Cβ resonance signals were assigned using the HNCACB,
HN(CO)CACB, and 15N NOESY-HSQC experiments. The assigned 1H–15N TROSY–
HSQC spectrum is showed in Figure 2A. Although the amino acid sequence of Kelch
contains regions of degeneracy (Figure 2B), we were able to assign 92 % of the 1HN and
15
N resonances of the non-proline residues, 91.6 % of 13Cα and 90.7 % of 13Cβ of all
residues. The chemical shift assignments of the human Kelch domain are comparable to
the assignments of the Kelch domain of mouse Keap1 that we have completed previously
[43].
To probe the conformational changes of Kelch upon mutations, 1H-15N TROSYHSQCs of G364C, R415G, G350S, and A427V were collected and compared to the
spectrum of wild-type Kelch (Figures S3A-D). The dispersion of the amide peaks for all
four mutants is similar to that of the wild-type Kelch, indicating that the mutants remain
well-folded. Further analysis of the chemical shift perturbations (Figure 3) revealed that
A427V displayed the largest amplitude of peak shifts followed by G364C, R415G and
G350S. It is noteworthy that large chemical shift changes are observed for some residues
that are located far from the mutation sites in the protein sequence for A427V, G364C
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and R415G mutants. For instance, A427 is located in the middle of the second β-strand
of Blade III. Mutating of this residue to a valine caused peak shifts of a significant
number of residues clustered in Blade II (residues V360-M409) and Blade III (S410L457), in particular, S363, G379, E446 and A466 residues (Figure 3C). The S363 and
G379 residues also undergo a substantial change in the G364C spectrum (Figure 3B).
Effects of mutations on the target recognition of the Kelch domain
We used NMR and ITC to assess the effects of mutations (G350S, G364C,
R415G and A427V) on the target recognition of the Kelch domain of Keap1. First,
peptides encoding the previously reported Neh2-ETGE (residues 69-84) [38], Neh2-DLG
(residues 20-39) [41], and ProTα-ENGE (residues 33-52) [31] Kelch-binding motifs
were used in the studies. NMR experiments allowed to elucidate the relative
contributions from Kelch residues (wild type and mutants) involved in the interactions
with Neh2-ETGE, Neh2-DLG, and ProTα-ENGE. Figures 4A & C show the 1H-15N
HSQC spectra of the wild-type Kelch domain in the presence of 5 molar equivalents of
unlabeled Neh2-ETGE and ProTα-ENGE peptides, respectively. Quantitative analysis of
the Kelch chemical shift perturbations revealed large changes in S363, G417, G462,
S508, G527, and T576 in the Neh2-ETGE and ProTα-ENGE bound state (Figures 5A &
C). Some of these residues are directly involved in complex formation with targets,
whereas the peak shift of others may be due to the changes in their local chemical
environment [36, 40, 41]. For example, S363 was found to form a hydrogen bond with
the E46 of ProTα in the complex [40]. Meanwhile, the G462 residue does not interact
with ProTα directly, rather it forms a intramolecular hydrogen bond with R415 which is
involved in a salt bridge with E43 of ProTα [40].
The amplitudes of chemical shift changes of G350S and A427V upon binding to
the Neh2-ETGE and ProTα-ENGE peptides were comparable to those of the wild-type
(Figures 5A & C, Figure S4C & D, Figure S5C & D). G364C and R415G displayed
smaller amplitudes of chemical shift perturbations upon binding to the Neh2-ETGE and
ProTα-ENGE peptides (Figures 5B & D, Figures S4A & B, Figures S5A & B). Despite
the difference in the amplitudes of changes, the overall chemical shift perturbation
pattern is similar to the wild-type, suggesting that in the presence of either one of these
two mutations, Kelch can still bind to the Neh2-ETGE and ProTα-ENGE peptides in
similar modes, but likely with lower affinities.
Meanwhile, titration of the Neh2-DLG peptide to the wild-type Kelch domain
(Figures 4B & 5E) results in overall smaller chemical shift changes of the protein,
suggesting that the Neh2-DLG peptide only forms weak interactions with Kelch.
Noticeable resonance shifts were observed for R354, D385, H436 and A607. The H436
residue was found to interact with the conserved G430 residue. The chemical
environment of the G430 is influenced by the R415 residue, which takes part in hydrogen
bonding with the targets [41]. Similarly, the chemical environment of other Kelch
residues undergoing large peak shifts are affected by amino acids involved in hydrogen
bonding with targets.
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Figures S6A-D show the 1H-15N HSQC spectra of G364C, R415G, G350S, and
A427V in the absence and presence of five molar equivalents of the Neh2-DLG peptides.
For the G350S and A427V mutants, while many resonance signals broaden out in the
ligand-bound state, both mutants display similar chemical shift attenuation patterns as the
wild-type Kelch. Meanwhile, the relatively minor chemical shift changes observed for
the G364C and R415G upon addition of DLG peptides indicate that the complex
formation is severely disrupted by the mutations (Figure 5F and Figures S6A & B). In
fact, for the G364C, we observe no significant peak broadening and only minor
resonance perturbations across the whole spectrum. The minor shifts observed in the
bound state NMR spectra of G364C-DLG complex and R415G-DLG complex suggest
that the presence of either one of these two somatic mutations in the Kelch domain can
depress the ability of Keap1 to interact with the DLG motif of Neh2.
We then used ITC to further quantify the effects of mutations on the target
binding of the Kelch domain. Table 1 lists the binding parameters of the wild-type and
mutants of the Kelch domain to the ProTα-ENGE and Neh2-ETGE peptides (ITC
profiles are shown in Figure S7). The dissociation constant (Kd) of the wild-type
Kelch/ProTα-ENGE and Kelch/Neh2-ETGE complexes were determined to be 2.7 ± 0.1
µM and 31 ± 2 nM, respectively. These values are on par with the values of ~2.6 µM and
~20 nM for Kelch complex formation with full-length ProTα and with a 16-mer Neh2ETGE peptide as reported in the literature [31, 36]. The binding affinities of the mutants
to ProTα and Neh2-ETGE peptides varied. While the G350S mutation has only minor
effects on the target binding (3.0 ± 0.1 µM for the ProTα-ENGE and to 38 ± 4 nM for the
Neh2-ETGE peptides), the G364C mutation lowered the binding affinity for both Neh2ETGE and ProTα-ENGE peptides by >10 fold compared to the wild-type complex (31 ±
2 µM for the ProTα-ENGE and to 345 ± 12 nM for the Neh2-ETGE peptides). Our ITC
data show that the interactions of G364C with targets are enthalpically less favorable
compared to the wild-type interactions. Replacement of the Gly residue with a Cys may
restrict the conformational freedom of the neighboring region and/or possibly disrupt the
wild-type hydrogen bond network.
The binding affinities of Kelch to both the ProTα-ENGE and Neh2-ETGE
peptides were severely impaired by the R415G mutation to an extent that the affinities
could not be accurately determined by ITC (Figures S7D & I). Intriguingly, in contrast to
G350S, G364C and R415G, the interactions with ProTα-ENGE and Neh2-ETGE
peptides were modestly strengthened with the A427V mutation. The Kd values are 1.90 ±
0.04 µM and 16 ± 2 nM, respectively (Table 1). Interestingly, A427V/ProTα-ENGE
complex formation was enthalpically more favorable, while the entropy change is more
negative in comparison with the wild-type.
We also attempted to measure the binding affinities of a 20-residue Neh2-DLG
peptide (encoding the sequence of I20-F39 of Nrf2) [41] to the wild-type Kelch domain
(Figure S7K) and the four mutants; however, no binding was detected by ITC at 25°C in
any case. NMR titration experiments, which were performed with higher concentrations
of protein and peptide, however showed that Neh2-DLG is capable of forming complex
with the Kelch domain (Figure 4B), likely with low binding affinity. Our results
11

suggested that either the interaction between the Kelch domain and the Neh2-DLG
peptide is very weak for ITC measurement or the ΔH of the binding is close to zero. No
detectable binding was observed at 5 and 35 oC either (data not shown). This observation
is in good agreement with the results obtained very recently by Fukutomi et al. [47]
showing that the binding of the Kelch domain with a 16-mer peptide containing the
previously defined DLG motif of Nrf2 (residues 22-37) was too weak to be detected by
differential scanning fluorimetry. Intriguingly, in the same study and experiment,
binding was detected using an extended DLG peptide comprising residues 17-51
(DLGex) of Nrf2, which suggests that residues flanking the DLG motif are critical for
binding to Kelch.
We investigated the binding of the Kelch domain to the DLG site in the context of
full-length Neh2 using a Neh2ΔETGE construct (deletion of 79ETGE82 from full-length
Neh2). Notably, NMR binding experiments of the Neh2ΔETGE with the Kelch domain
reveal significant chemical perturbations in the N-terminal residues 6 to 40 of
Neh2ΔETGE (Figure S8). Resonance broadening occurring in a large number of
flanking residues supports the findings by Fukutomi et al. [47] that the DLG motif is
indeed longer than previously defined [41]. Figures S9A-E show the isotherms for the
binding of the Neh2ΔETGE protein to the Kelch domain at 25 °C, 20 °C, 15 °C, 10 °C
and 5 °C, respectively. It is apparent that the complex formation is endothermic at low
temperatures and as the temperature increases, the enthalpy change becomes smaller.
Table S4 lists the thermodynamic parameters for the Neh2ΔETGE-Kelch complex at 5
°C and 10 °C. With the buffer conditions used in this study, the Kd of the human
Neh2ΔETGE/Kelch binding was determined to be ~351 ± 16 nM at 10 oC. The value is
similar to what was determined for the mouse Kelch binding to the Neh2ΔETGE (Kd
~128 nM) [47], as well as to DLGex peptide (residues 17-51, Kd ~526 nM) at 25 oC [47].
We then estimated the ΔCp value based on the ΔH values at the 5 °C and 10 °C. Based
on the calculated ΔCp value of -0.47 kcal mol-1 K-1, the ΔH at 25 oC was estimated to be
~-1.2 kcal/mol. This small value of enthalpy change explains why binding between the
Neh2ΔETGE and the Kelch domain could not be observed at 25 oC by ITC.
Somatic mutations in the Kelch domain affect its interaction with the full-length
Neh2 domain
To examine how the somatic mutations in the Kelch domain affect its interactions
with the DLG and ETGE sites in the context of full-length Neh2, ITC experiments were
carried out at 5 °C to determine the binding parameters of the wild-type Kelch and four
mutational variants with the Neh2 domain (residues 1-98) of Nrf2. Kelch proteins were
titrated to the full-length Neh2 and the ITC isotherms were fit to either a two-site or onesite binding model. The results are listed in Table 2 (Figures S9F-J shows the ITC
isotherms). Similar to what was observed for the binding of the Kelch domain to the
Neh2-ETGE peptide, both R415G and G364C mutations dramatically weakened Kelch’s
interaction with the ETGE site of the full-length Neh2. Compared to the wild-type
Kelch, which binds the ETGE site with a Kd of 1.26 ± 0.03 nM, G364C and R415G have
binding affinities that are 37 and 870 fold lower, respectively. On the other hand, the
G350S and A427V mutations show no significant impact on the ETGE binding. It is
noteworthy that the binding affinities of the Neh2-ETGE motif to the wild-type and
12

mutational variants of Kelch are tighter when present in the full-length Neh2 protein as
opposed to a peptide. For instance, the Kelch R415G provided a measurable affinity (Kd
of 1.1 µM) when titrated into full-length Neh2 but could not be accurately determined for
the ETGE peptide (Figures S7I & S9I).
As also observed for the mouse Kelch-DLG complexes [30, 47], the DLG site in
the context of full-length human Neh2 binds significantly weaker to the Kelch domain
compared to the ETGE site (Kd of 179 nM vs 1.26 nM). For the mutants, the binding
affinity of the G350S to the DLG site decreased by less than two-fold while the A427V
mutant has the same affinity (Kd of 179 ± 4 nM) as compared to the wild-type. Our ITC
data is in accordance with the NMR results, indicating that in the presence of either
A427V or G350S mutations, the Kelch domain should still be able to interact effectively
with both the ETGE and DLG sites of Nrf2. On the other hand, the interactions of the
DLG site with G364C and R415G could not be detected by ITC (Figures S9H & I) even
in the context of full length Neh2, while the ETGE site interacts with R415G and G364C
but with lower affinities.
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DISCUSSION
In this work, we have characterized the effects of cancer-associated somatic
mutations on structure and target recognition of Keap1. Nine mutations identified in lung
cancer patients or cancer cell lines, were studied based on their location in the Kelch
domain (Table S1). ITC, CD and NMR techniques were used to quantify the binding
parameters of these mutational variants with two of the binding targets of Keap1 and to
assess the conformational changes these mutations induce on the Kelch structure. Our
results indicated that the disease-linked somatic mutations have differential effects on the
structural integrity and the target recognition of Keap1.
The G333, G379, G430, G476 and R413 residues are conserved in the Kelch
domain. Our protein expression, purification and NMR data (Figures S1) suggest that
mutating these residues can result in the unfolding/misfolding of the Kelch domain.
Further in vivo experiments are required to verify these findings. As mentioned earlier,
the G333, G379, G430 and G476 all play key roles in the folding of the Kelch domain
[39]. The crystal structure of the human Kelch domain (PDB: 1U6D) shows that the
backbone torsion angles of these four glycines are generally located in disallowed
regions. Therefore, mutating these residues to any other amino acid with a β-carbon side
chain may induce severe conformational strain in the structure, causing the protein to
unfold/misfold. Previous studies using immunoprecipitation and luciferase assays have
demonstrated that the G333C, G379D, and G430C mutants are defective in repressing
Nrf2-mediated transcription of cytoprotective genes [12, 15, 16]. In agreement with
these findings, our results suggest that reduction in protein stability of Keap1 is the cause
of the loss-of-function of these mutants. We speculate that any other mutations occurring
in the double glycine repeats (e.g. G333S and G524C listed in the COSMIC database)
will be detrimental to Kelch’s structural integrity [12, 15, 16].
Although the 1H-15N HSQC spectrum of Kelch R413L resembled that of a folded
protein (Figure S1C), the mutant is not stable compared to the wild-type Kelch. R413,
located in Blade III, is one of the conserved Arg residues found in all six blades of the βpropeller structure [39]. The side-chain of this residue is involved in inter-blade
hydrogen bonding with G379, the first residue of the glycine doublet in Blade II [39]. It
has been suggested that the inter-blade hydrogen bonding between these conserved Arg
and Gly residues are important for maintaining the Kelch structure [39]. Our results
demonstrated that a single point mutation in the R413 position is sufficient to destabilize
the protein, and probably leads to the loss of function. The impacts of mutations of other
conserved Arg residues (e.g. R362Q, R460G, R460S, R554Q [32], and R601W listed in
COSMIC) on the protein stability remain to be elucidated.
Unlike the G333C, G379D, R413L, G430C, and G476R mutants, G350S, G364C,
R415G, and A427V have comparable solubility to the wild-type protein. CD analysis of
these four mutational variants illustrated that they all possess similar secondary structure
contents as the wild-type (Figure S2). On the other hand, our ITC results clearly
demonstrated that, depending on their locations in the protein, these four mutations exert
differential impacts on the target binding of the Kelch domain (Tables 1 & 2). The G350
residue is located in a loop region at the opposite face of the ligand-binding pocket of the
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β-propeller structure, forming a hydrogen bond with the neighboring N346 residue [39].
Crystal structures of the Kelch domain in complex with the Neh2-ETGE, Neh2-DLG, and
ProTα-ENGE peptides revealed that this residue was not directly involved in the
interactions with targets [36, 40, 41]. Even though the G350S mutation has been
identified in non-small-cell lung cancer cell lines [12] and gastric cancer tissue [33], the
mutation appears to cause no substantial changes to the binding of ProTα or the Neh2
domain of Nrf2: only a 1-2 fold decrease in the binding affinity to ProTα-ENGE, Neh2ETGE, and Neh2-DLG motifs compared to the wild-type Kelch were observed. NMR
data further demonstrate that the G350S mutation does not lead to any significant change
in the protein structure. Together, our results suggest that this particular mutation does
not hamper the complex formation of Keap1 with Nrf2 and ProTα. Effects of this
mutation on the interactions of Keap1 with other targets, however, remain to be
investigated [32, 42].
The Kelch A427V is another cancer-linked mutation (identified in cancer tissue of
a patient with small cell carcinoma [16]) that was observed to interact with Nrf2 and
ProTα with similar affinities to wild-type Kelch. In fact, this particular Ala to Val
substitution resulted in modest increases (~ 2 fold) in the binding affinity of Kelch to
ProTα-ENGE and Neh2-ETGE peptides (Table 1). Our NMR results further confirm that
the binding of this mutant to ProTα-ENGE, Neh2-ETGE and Neh2-DLG motifs are
similar to the wild-type interactions with targets. Intriguingly, while the G350S mutation
resulted in subtle chemical shift changes to residues around the mutation site (Figure 3A),
the A427V mutation, found in the β2 strand of blade III, leads to local structural changes
in blades II and III, which are reflected by the substantial chemical shift changes
observed (Figure 3C). However, these local structural changes do not impair the binding
of Kelch to either Neh2 or ProTα. Since the Kelch domain of Keap1 also mediates the
interaction with WTX [22], p62 [23], PGAM5 [24], PALB2 [25], FAC1 [26], IKKβ [27],
and many other proteins [28], characterizing the effect of the A427V mutation on the
binding of these targets will provide further insight into the links of this particular
somatic mutation to the associated disease. It is noteworthy that Hast et al. [32] recently
reported that the R470C, D422N, and G423V mutations also increase the binding to Nrf2
compared to the wild-type Keap1 based on their immunoprecipitation and Western blot
analysis. However, the molecular effects of these cancer-associated mutations on the
structure of Kelch remain unknown. Interestingly, Baird et al. have demonstrated that
sulforaphane, a well-known Nrf2-inducer, can enhance the interaction between Keap1
and Nrf2 by provoking conformational changes to the complex [48]. Despite the tighter
interaction between these two proteins, it has been suggested that Nrf2 is not properly
oriented in the induced state for ubiquitination by the E2 ubiquitin-conjugating enzyme
[48]. In light of this finding, it is possible that some of these tighter binding mutants may
induce subtle changes to the mode of Keap1-Nrf2 interaction, rendering the
ubiquitination/degradation of Nrf2 ineffective [32, 48].
Meanwhile, our ITC and NMR results show that both the G364C and R415G
mutations impair Kelch’s ability to interact with Nrf2 and ProTα, albeit to different
extents. The G364C substitution resulted in significantly lower affinity for both Neh2ETGE and ProTα-ENGE peptides (Kd (Neh2-ETGE) = 345 nM and Kd (ProTα-ENGE) =
15

31 µM vs Kd (Neh2-ETGE) = 31 nM and Kd (ProTα-ENGE) = 2.7 µM for the wild-type
Kelch). The substantial decrease in affinity for the ETGE motif was also observed in the
context of full-length Neh2 domain (Kd = 47 nM vs Kd = 1.26 nM for wild-type Kelch).
The crystal structure of the human Kelch domain in complex with the ETGE peptide
illustrates that G364 has φ/ψ torsion angles of left-handed helix and is not involved in
hydrogen bonding with the target. However, this Gly residue is located next to S363,
which forms hydrogen bonds with E82 of the ETGE peptides [36, 40]. Replacing the
Gly with a Cys residue may restrict the orientation of the S363 side chain from forming
hydrogen bonds with E82. Additionally, the G364C mutation may also affect the intramolecular hydrogen bonding with the G603 residue [39]. It is noteworthy that even
though the G364C and R415G mutations significantly weaken the interactions of Kelch
with ProTα-ENGE and the Neh2-ETGE motifs, low binding affinities with these two
targets could still be measured. On the other hand, no interaction between these two
mutants and the DLG motif (even in the context of full-length Neh2) could be detected
by ITC.
The R415 residue of Kelch is directly involved in the binding with targets [23, 36,
40]. In the mouse Keap1-ProTα peptide complex, R415 is involved in electrostatic
interactions with the E43 residue of ProTα [40]. This Arg residue also forms salt bridges
with the E79 residue in the binding interface with the Neh2-ETGE peptide [36]. As such,
it is not a surprise that replacing this critical Arg residue in the positively charged pocket
with a non-polar Gly can significantly weaken the interactions of the Kelch domain with
its targets, and this was observed in our ITC and NMR binding studies with ProTα and
Neh2. In agreement with this, a study by Tong et al. [30], which replaced R415 with a
Lys also attenuated the binding of Kelch to the ETGE motif of Neh2 domain. Similarly,
Lo et al. [36] detected no Nrf2 repressive activity for the R415A mutant. We speculate
that mutations of other residues that are in direct contact with the ETGE and DLG motifs
of Neh2 (e.g. Y334H, R483C, S555C, and Y572C) will ultimately impair the interaction
of Keap1 with Nrf2. Further in vivo and in vitro experiments will allow correlating the
molecular effects of different categories of mutations with their impacts on the Nrf2repression function systematically.
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Table 1. Thermodynamic parameters for the binding of the Neh2 and ProTα
peptides to the Kelch domain of human Keap1 at 25 °C
ENGE peptide
of ProTα
Wild-type
Kelch
G350S
G364C
R415G
A427V
ETGE peptide
of Neh2
Wild-type
Kelch
G350S
G364C
R415G
A427V

n*

Ka*
(105 M-1)
3.78 ± 0.15

Kd *
(µM)
2.65 ± 0.11

ΔH*
(kcal/mol)
-17.1 ± 0.2

TΔS*
(kcal/mol)
-9.50

ΔG*
(kcal/mol)
-7.60 ± 0.02

1.03 ± 0.007

3.33 ± 0. 07
0.32 ± 0.02
5.25 ± 0.1
Ka*
(107 M-1)
3.18 ± 0.23

3.00 ± 0.06 -18.1 ± 0.6
31.3 ± 2.0 -14.17 ± 0.2
1.90 ± 0.04 -22.4 ± 0.1
Kd *
ΔH*
(nM)
(kcal/mol)
31.4 ± 2.3 -20.4 ± 0.09

- 10.58
-8.03
-14.60
TΔS*
(kcal/mol)
-10.17

-7.52 ± 0.01
-6.14 ± 0.04
-7.80 ± 0.02
ΔG*
(kcal/mol)
-10.23 ± 0.04

1.01 ± 0.005
1.07 ± 0.03
1.11 ± 0.002

2.65 ± 0.3
0.29 ± 0.01
6.44 ± 0.67

37.7 ± 4.3
345 ± 12
15.5 ± 1.6

-8.78
-2.72
-8.95

-10.12 ± 0.06
-8.81 ± 0.02
-10.65 ± 0.06

1.07 ± 0.004
0.92 ± 0.02
0.98 ± 0.01
1.06 ± 0.003
n*

*

-18.9 ± 0.17
-11.53 ± 0.4
-19.6 ± 0.13

n is the stoichiometry, Ka, and Kd are the association and dissociation constants,
respectively. ΔG = ΔH-TΔS = -RTln Ka, where T is the temperature in Kelvin, R is the
gas constant. ΔH and ΔS are the enthalpy and entropy changes, respectively. The
corresponding ITC isotherms are shown in Figure S2 in supplemental data. Values listed
in the table are based on one run, and the data for the duplicate run is provided in the
supplementary data (Table S3).
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Table 2. Thermodynamic parameters for the binding of the wild-type and
mutational variants of Kelch to the ETGE and DLG sites of full length Neh2 at 5°
C.
Protein

n

Kelch ETGE
DLG
G350S ETGE
DLG
G364C ETGE
DLG
R415G ETGE
DLG
A427V ETGE
DLG

0.90 ±
0.00(3)
0.93 ± 0.02

Ka
(107 M-1)
79.2 ± 2.07
0.56 ± 0.012

Kd
ΔH
(nM)
(kcal/mol)
1.26 ± 0.03 -20.34 ± 0.12
179 ± 4

9.04 ± 0.03

0.91± 0.01
60.9 ± 2.99 1.64 ± 0.08 -20.13 ± 0.07
0.93 ± 0.01 0.35 ± 0.014
286 ± 11 10.61 ± 0.12
0.92 ± 0.01 2.15 ± 0.18
46.5 ± 3.9 -15.09 ± 0.06
1.03 ± 0.01 0.091 ± 0.008 1099 ± 97 -13.35 ± 0.12
0.91 ± 0.01
79.1 ± 4.9 1.26 ± 0.08 -20.17 ± 0.17
1.00 ± 0.03 0.56 ± 0.021
179 ± 7
9.44 ± 0.10

TΔS
(kcal/mol)
-9.02

ΔG
(kcal/mol)
-11.32 ± 0.01

17.62

-8.58 ± 0.01

-8.96
18.93
-5.77
-5.77
-8.85
18.02

-11.17 ± 0.03
-8.32 ± 0.02
-9.32 ± 0.04
-7.58 ± 0.05
-11.32 ± 0.03
-8.58 ± 0.02

The isotherms of wild-type Kelch, G350S and A427V mutants were fit to a two-sitebinding model, assuming that the binding affinities of the ETGE motif are higher than
that of the DLG motif. The isotherms of G364C and R415G mutants were fit to a onesite-binding model. n is the stoichiometry, Ka, and Kd are the association and dissociation
constants, respectively. ΔG = ΔH – TΔS = -RTlnKa, where T is the temperature in
Kelvin, R is the gas constant, ΔH and ΔS are the enthalpy and entropy changes,
respectively. Values listed in the table are based on one run, the data for the duplicate run
is provided in the Supplementary Data (Table S5).
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FIGURE LEGENDS
Figure 1. Crystal structure of Kelch with Neh2 and mutation sites located in the
Kelch domain of Keap1 (PDB:1U6D [36, 39]). (A) Domain scheme of Keap1 (B)
Neh2-ETGE peptide bound to Kelch domain (PDB: 2FLU [36]). (C) Somatic mutations
occurring in the binding interface. (D) Mutations found outside the binding interface. (E)
Mutations in the conserved double glycine repeats.
Figure 2. Backbone resonance assignments of the Kelch domain of human Keap1 (A)
1
H-15N HSQC spectrum of 2H/15N/13C labeled Kelch domain of Keap1. (B) Amino acid
sequence of the Kelch domain, unassigned residues are colored in red. Amino acids
appearing in grey are residual residues from the affinity tag.
Figure 3. 1HN and 15N chemical shift changes of the Kelch mutants. Residues with
traceable assigned resonances are colored based on composite 1HN and 15N chemical shift
changes (Δδ=[(ΔδHN)2+(ΔδN/5)2]1/2 in ppm). (A) G350S, (B) G364C, (C) A427V and (D)
R415G.
Figure 4. 1H-15N HSQC NMR spectra of the wild-type Kelch domain in the absence
(black) and presence (red) of five molar equivalents of Neh2-ETGE peptide (A), Neh2DLG peptide (B), and ProTα peptide (C).
Figure 5. Composite 1HN and 15N chemical shift perturbation (Δδ=[(ΔδHN)2+(ΔδN/5)2]1/2)
analysis of the wild type and the four mutants in the presence of two molar equivalents of
ProTα peptide (A, B), two molar equivalents of Neh2-ETGE peptide (C, D), and five
molar equivalents of Neh2-DLG peptide (E, F). The boundaries of the propeller blades
are defined based on [39].
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Table S1. Somatic mutations included in this study†.
Type

Location in
Kelch

Specimen

Cancer
type

G364C

Blade II

Lung (ADC)

R415G

Blade III

Cell line
H1648
Patient

R413L

Blade III

Patient

Lung

G350S

Blade I

Lung

A427V

Blade III

Cell lines and
Patient
Patient

Lung (SCC)

G333C

Blade I

Cell line A549

Lung

G379D

Blade II

Patient

G430C

Blade III

Patient

Gall Bladder
(ADC)
Lung (ADC)

G476R

Blade IV

Patient

Lung (LCC)

Lung (ADC)

Abbreviations: ADC: Adenocarcinoma, SCC: Small cell carcinoma, LCC: Large cell
carcinoma. †Reference: Hayes & McMahon (2009) Trends Biochem Sci, 34, 176-188
[11].

1

Figure S1. 1H-15N HSQC NMR spectra of G333C (A), G379D (B), and R413L (C)
mutants of the Kelch domain.

2

Figure S2. CD spectra of wild-type Kelch (black), G350S (red), G364C (blue), R415G
(green), and A427V (orange).

3

Table S2. Deconvulated CD data of the WT Kelch and mutational variants
Protein
WT-Kelch
G350S
G364C
R415G
A427V

Helix
0.063
0.063
0.063
0.062
0.061

β-sheet
0.432
0.433
0.432
0.415
0.436

4

Turn
0.120
0.120
0.118
0.120
0.119

Unordered
0.385
0.384
0.386
0.394
0.384

Figure S3. Overlay of the 1H-15N TROSY-HSQC NMR spectra of wild-type Kelch
(black) and G364C (A), R415G (B), G350S (C), and A427V (D).

5

Figure S4. Overlay of the 1H-15N HSQC NMR spectra of the G364C (A), R415G (B),
G350S (C), and A427V (D) Kelch mutations in the absence (black) and presence
(orange) of a two molar equivalent of the Neh2-ETGE peptide.

6

Figure S5. Overlay of the 1H-15N HSQC NMR spectra of the G364C (A), R415G (B),
G350S (C), and A427V (D) Kelch mutations in the absence (black) and presence
(orange) of a two molar equivalent of the ProTα-ENGE peptide.

7

Figure S6. Overlay of the 1H-15N HSQC NMR spectra of the Kelch G364C (A), R415G
(B), G350S (C), and A427V (D) mutations in the absence (black) and presence (orange)
of a five molar equivalent of the Neh2-DLG peptide.

8

Table S3. Thermodynamic parameters for the binding of the Neh2 and Prothymosin α
(ProT α) peptides to the human Kelch domain of Keap1 at 25 °C (duplicate run).
ENGE peptide
of ProTα
Wild-type
Kelch
G350S
G364C
R415G
A427V
ETGE peptide
of Neh2
Wild-type
Kelch
G350S
G364C
R415G
A427V

n*

Ka*
(105 M-1)
4.01 ± 0.2

Kd *
ΔH*
(µM)
(kcal/mol)
2.49 ± 0.12 -17.7 ± 0.12

TΔS*
(kcal/mol)
-10.07

ΔG*
(kcal/mol)
-7.64 ± 0.03

1.01 ± 0.002

2.73 ± 0.05
0.29 ± 0.01
5.24 ± 0.2
Ka*
(107 M-1)
3.43 ± 0.5

3.66 ± 0.07
34.5 ± 1.2
1.91 ± 0.07
Kd *
(nM)
29.2 ± 4.4

-11.79
-9.82
-14.50
TΔS*
(kcal/mol)
-10.73

-7.41 ± 0.01
-6.08 ± 0.02
-7.80 ± 0.02
ΔG*
(kcal/mol)
-10.27 ± 0.09

1.0 ± 0.003
1.08 ± 0.03
1.05 ± 0.003

2.62 ± 0.3
0.4 ± 0.02
4.33 ± 0.5

38.2 ± 4.3 -19.2 ± 0.11
250 ± 13 -10.63 ± 0.04
23.1 ± 2.7 -19.7 ± 0.19

-9.09
-1.63
-9.29

-10.11 ± 0.06
-9.0 ± 0.03
-10.41 ± 0.07

1.03 ± 0.005
0.96 ± 0.003
1.06 ± 0.2
1.04 ± 0.004
n*

-19.2 ± 0.11
-15.9 ± 0.03
-22.3 ± 0.15
ΔH*
(kcal/mol)
-21.0 ± 0.18

*n is the stoichiometry, Ka, and Kd are the association and dissociation constants,
respectively. ΔG = ΔH-TΔS = -RTlnKa, where T is the temperature in Kelvin, R is the
gas constant. ΔH and ΔS are the enthalpy and entropy changes, respectively. Values listed
in the table are based on one run, and the data for the duplicate run is provided in Table 1.

9

Figure S7. ITC profiles of titrating ProTα-ENGE peptide to wild-type Kelch (A), G350S
(B), G364C (C), R415G (D), and A427V (E), respectively; (F-J) show the ITC profiles of
titrating Neh2-ETGE peptide to wild-type Kelch (F), G350S (G), G364C (H), R415G (I),
and A427V (J), respectively; (K) ITC profile of titrating Neh2-DLG peptide to wild-type
Kelch.

10

Figure S8. 1H-15N HSQC of Neh2ΔETGE in the free (black) and Kelch bound (orange)
state. Many residues in the N-terminal region (L6, L11, S13, Q14, L23, R25 Q14, D16,
I20, W24, I28, D29, L30, G31, V32, S33, R34, F37, F39 and S40) of Neh2 undergo
substantial perturbations suggesting that these flanking residues contribute to the DLG
motif interaction with the Kelch domain.
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Figure S9. ITC profiles of titrating wild-type Kelch to Neh2ΔETGE at 25 oC (A), 20 oC
(B), 15 oC (C), 10 oC (D), and 5 oC (E), respectively. (F-J) shows the ITC profiles of
titrating wild-type Kelch (F), G350S (G), G464C (H), R415G (I), and A427V (J),
respectively, to full-length Neh2 at 5oC.
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Table S4. Thermodynamic parameters for the binding of the Kelch domain of
Keap1 to Neh2ΔETGE at different temperatures
n*

Ka*
(106 M-1)

Kd *
(nM)

ΔH*
(kcal/mol)

TΔS*
(kcal/mol)

ΔG*
(kcal/mol)

Titration set 1
5
10

0.90 ± 0.03
1.02 ± 0.17

3.03 ± 0.14
2.85 ± 0.13

330 ± 15
351 ± 16

8.13 ± 0.11
5.80 ± 0.06

16.37
14.16

-8.24 ± 0.03
-8.36 ± 0.03

Titration set 2
5
10

1.10 ± 0.02
0.97 ± 0.02

3.13 ± 0.18
2.66 ± 0.11

319 ± 18
376 ± 16

8.70 ± 0.15
5.64 ± 0.04

16.96
13.96

-8.26 ± 0.03
-8.32 ± 0.02

Temp (° C)

*

n is the stoichiometry, Ka, and Kd are the association and dissociation constants,
respectively. ΔG = ΔH – TΔS = -RTlnKa, where T is the temperature in Kelvin, R is the
gas constant. ΔH and ΔS are the enthalpy and entropy changes, respectively.
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Table S5. Thermodynamic parameters for the binding of the Kelch and Kelch
mutational variants to the ETGE and DLG sites of full length Neh2 at 5° C
(duplicate runs).
Protein

n

Kelch ETGE
DLG
G350S ETGE
DLG
G364C ETGE
DLG
R415G ETGE
DLG
A427V ETGE
DLG

1.06 ± 0.04

Ka
(107 M-1)
73.3 ± 1.84

1.12 ± 0.02

0.46 ± 0.010

Kd
ΔH
(nM)
(kcal/mol)
1.36 ± 0.03 -19.02 ± 0.08
217 ± 5

8.46 ± 0.10

1.07± 0.01
51.8 ± 1.79 1.93 ± 0.07 -19.83 ± 0.13
1.1 ± 0.03 0.36 ± 0.011
278 ± 8
9.52 ± 0.09
0.92 ± 0.01 2.34 ± 0.12
42.7 ± 2.2 -15.0 ± 0.12
1.0 ± 0.01 0.089 ± 0.008 1124 ± 101 -13.40 ± 0.05
0.91 ±
68.4 ± 1.95 1.46 ± 0.04 -20.69 ± 0.14
0.00(3)
1.00 ± 0.01 0.53 ± 0.014
189 ± 5
9.52 ± 0.02

TΔS
(kcal/mol)
-7.74

ΔG
(kcal/mol)
-11.28 ± 0.01

16.93

-8.47 ± 0.01

-8.74
17.86
-5.63
-5.83
-9.45

-11.08 ± 0.02
-8.34 ± 0.02
-9.37 ± 0.03
-7.57 ± 0.05
-11.24 ± 0.02

18.07

-8.55 ± 0.01

The isotherms of wild-type Kelch, G350S and A427V mutants were fit to a two-sitebinding model, assuming that the binding affinities of the ETGE site are higher than that
of the DLG site. The isotherms of G364C and R415G mutants were fit to a one-sitebinding model. n is the stoichiometry, Ka, and Kd are the association and dissociation
constants, respectively. ΔG = ΔH – TΔS = -RTlnKa, where T is the temperature in
Kelvin, R is the gas constant, ΔH and ΔS are the enthalpy and entropy changes,
respectively.
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